OA01.06 First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study

Tislelizumab, an anti-programmed cell death protein 1 monoclonal antibody, in combination with chemotherapy, showed promising antitumor activity in patients with extensive-stage small-cell lung cancer (ES-SCLC) receiving first-line treatment in the phase 2 BGB-A317-206 study. Here, we present the final analysis of the randomized, double-blind, placebo-controlled, phase 3 RATIONALE-312 study (NCT04005716), which compared efficacy and safety of tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line treatment in patients with ES-SCLC.